Cagrilintide — Benefits, Dosage & Where to Buy

Research Overview

Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for the treatment of obesity and type 2 diabetes. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells that promotes satiety, slows gastric emptying, and suppresses glucagon secretion. Cagrilintide mimics these effects with a much longer half-life, allowing once-weekly dosing. The combination of cagrilintide with semaglutide (marketed as CagriSema) has shown weight loss results exceeding either compound alone in clinical trials, with participants losing up to 15-20% of body weight. Phase 3 trials are ongoing, and CagriSema is expected to become a major competitor to tirzepatide in the obesity drug market.